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Abstract 
NC-1007 (CK4-M2GlyR) (PARVGLGITTVLTMTTQSSGSRAKKKK) is a synthetic peptide 
modeled after the second transmembrane segment of the spinal cord glycine receptor’s α-subunit, 
and has demonstrates the capacity to oligomerize to form transmembrane channels with Cl- 
permselectivity. While studies into the effects of truncation on both CK4 (C-terminal tetra-lysl 
adducted) and NK4 (N-terminal tetra-lysl adducted) led to more control over solution aggregation 
in the NK4 variant, the work presented explore whether C-terminal sequential substitutions with 
a tryptophan residue could similarly stabilize the aqueous structure in monomeric form or further 
define the pore registry in such a way as to promote an increase ion permeability. Tryptophan 
was substituted for amino acids in the 18th, 19th, 20th, and 21st positions of the peptide sequence 
(SSGS, respectively), and changes in aggregation profiles, secondary structure, and channel ion 
permeability were observed. Synthesized peptides show circular dichroism spectral profiles 
indicating that the studied tryptophan substitutions did not result in a reduction of the 
characteristic helicity of the peptide; however, the tryptophan substitution also did little to 
decrease solution aggregation as demonstrated by comparative studies by reverse-phase high-
performance liquid chromatography. All peptides demonstrated channel activity, directly 
measured by recordings of transepithelial short-circuit current. with profiles that suggest trends 
in electrostatic interactions and membrane registry relative to substitution position. One peptide 
in particular, NC-1007 S21W displayed atypical activity, which could not be effectively 
described by the standard Hill-based model but may be indicative of an ill-defined registry due to 
the substituted peptide’s proximity to another strongly pore-defining residue. Further studies in 
the effects of sequence modification to channel-forming peptides will elucidate how sequences 
may be altered to optimize synthetic peptide solubility, resistance to in-solution aggregation, and 
ability to form selective and permeable ion channels. The understanding gained from this study 
will improve our ability to develop peptides that could serve as a therapeutic treatments for a 
number of endogenous channelopathies.  
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Chapter 1 - Background and Introduction 
 Ion Channels 
Ion channels are protein complexes that allow for the movement of ions across cellular 
membranes. Ion channels often employ gating mechanisms dependent on ligands or voltage, and 
are defined by a number of characteristics of the pore that they form, including conductance, 
length, and dielectric constant (Futaki 1998; Stoikov et al., 2003). Ion channels are generally 
composed of proteins, some of which assemble to form a permeable pore. Pore size and residue 
type at or near the narrowest part of the channel, known as the selectivity filter, affect which ions 
can permeate through the channel (Ashcroft, 2000; Hille, 2001).  
 Amino acid residues can be positively or negatively charged (and therefore hydrophilic), 
uncharged but polar, or non-polar. Hydrophobic nonpolar residues tend to comprise the 
transmembrane domain of the protein, while hydrophilic residues tend toward the extra- or intra-
cellular space. Certain amino acid residues have somewhat predictable effects on the pore 
structure. For example, proline, due to its cyclic side-chain, displays notable conformational 
rigidity, and is frequently found at the terminus of the peptide’s α–helix, and therefore often 
defines the boundary of the transmembrane domain in membrane-spanning peptides and proteins 
(Ashcroft, 2000). Serine, threonine, and tyrosine can be phosphorylated to induce a negative 
charge, potentially altering the structure and function of the peptide or channel through this 
change in electrostatic interactions. Extracellular residues also may undergo glycosylation, 
adding mass that may have an effect on structure or function of the channel. It is generally 
assumed that transmembrane segments are often α–helical in secondary structure, comprised of 
16-20 amino acids, and often contain many alanine, glutamate, methionine, or leucine residues, 
which have a greater propensity for the formation of α–helical structures. 
This opening and closing mechanism of ion channels is known as gating, and can be 
driven by voltage changes or covalent modification of the peptide or protein. Single channel 
recordings can determine the channel’s opening and closing rates as well as conductance. The 
ratio of the time the channel is open to the total duration of the recording is known as the open 
probability, and can be used to calculate macroscopic current from single-channel current data if 
the number of channels and single channel current is known. This value can be obtained using 
the following equation:  
 
I=inPo 
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Where I is macroscopic current; i, single-channel current; n, the number of active channels; and 
Po, the probability of any given channel being open.  
The majority of channels have a single conductance state, meaning that during times 
spent open, given that the membrane potential is constant, the amplitude of current through the 
channel is consistent. In some cases, however, certain channels can demonstrate multiple 
conductance states. Current through a single channel varies with intra- and extra-cellular 
concentrations of present ion species, membrane voltage potential, and solubility. 
Electrochemical gradients determine the direction of movement through the pore, as well as flow 
rate (Ashcroft, 2000). 
 Ion Flux Across Epithelia 
A number of different ions flow into and out of an epithelial cell, impacting the 
membrane potential that serves as the driving force for ion movement. In order to understand Cl- 
transport through CFTR or M2GlyR peptides, it is important to understand the complex interplay 
of other transporters that affect net driving forces.  
Na+/K+ ATPase (a.k.a. Na+/K+ pump) contributes substantially to cellular energy 
expenditure, accounting for roughly 2/3 of ATP utilization. It is electrogenic, moving 3 Na+ and 
2 K+ against their concentration gradients (out of and into the cell, respectively). This plays a 
fundamental role in maintaining cellular potential and the electrochemical gradients that serve as 
the driving force for the secretion of other ions, such as Cl- (Skou, 1998). Similarly, K+ channels 
such as TWIK (two-pore domain weak inward rectifying K+ channel) related channels, such as 
TASK (TWIK-related acid-sensitive K+ channel) and TREK (TWIK-related K+ channel) and an 
abundance of Ca2+ activated K+ channels play a key role in maintaining voltage potential of the 
epithelial cell. In order to maintain polarization of the cellular resting potential, positively 
charged ions must be pumped out of the cell at a steady rate, counterbalancing the influx of 
positively charged Na+. This efflux of K+ thereby repolarizes the cell so as to promote anion 
efflux. The Na+/K+/2Cl- cotransporter (epithelial isoform NKCC1) mediates the uptake of 2 Cl- 
ions into the cell, driven by its coupled influx with one K+ and one Na+ ion (Frizzell & 
Hanrahan, 2012; Wills et al., 1996). In the typical epithelial cell, the concentrations of 
predominant ions Na+, K+, Ca2+, Cl-, and HCO3- play the most significant role in ion transport.  
Diffusive forces will generally drive ions to move down a gradient from high to low 
concentration. However, in biological systems electrical gradients can oppose those of diffusion, 
and depending on the system, there exists a certain equilibrium potential at which these forces 
are perfectly opposed such that there is no net ionic flux. Ohm’s law relates the electrical driving 
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forces and movement for ions current through a conductive pathway, and is defined in terms of 
current (I), conductance (G) and voltage (V), such that: 
 
 I = G*V  
 
The Nernst equation defines this voltage with respect to the ion’s valence and 
transmembrane concentration gradient. The Nernst equation can be expressed as:  
 
Ex = (RT/(z)F)*ln([X]ext/[X]int) or alternatively, 
Ex = (2.3RT/(z)F)*log([X]ext/[X]int) 
 
Where Vx is the equilibrium potential for the given ion; R is the universal gas constant, 8.314 
J/(mol*K); T is temperature in Kelvin (assumed at 310K for body temperature); z is ion valence 
(negative for anions, positive for cations); F is Faraday’s constant (9.6484 x 104 coulombs/mol); 
X is the given ion being evaluated (e.g. Cl-) and its extracellular ([X]ext) and intracellular ([X]int) 
concentrations.  
 The Nernst equation, however, is limiting in that it can only express the equilibrium 
potential relative to the intra- and extra-cellular concentrations of a single ion. In actuality, 
however, the membrane is permeable to multiple ions that contribute to the electrochemical 
gradient that drives ion flux. In the case of multiple ion transport, equilibrium potential is 
reached when the current relative to all ions in flux rests at zero. The Goldman-Hodgkin-Katz 
(GHK) equation can be used to calculate the membrane potential of a cell that is permeable to 
more than a single ion species, and is given as:  
 
,   
 
 
Where Vm is membrane potential; R, the universal gas constant; T, temperature in Kelvin; F, 
Faraday’s constant; px, the permeability of a given ion (in cm/sec); [X]o, the extracellular, and 
[X]i, the intracellular concentrations of the given ion; and K (K+), Na (Na+), and Cl (Cl-), the ions 
in question for epithelial membranes.  
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 The Glycine Receptor (GlyR) 
Cl- channels play functional roles in transepithelial transport as well as membrane 
excitability and cellular pH modulation. At least three distinct families of Cl- channel exist 
(Jentsch and Günther, 1997): voltage-gated channels, CFTR-like channels, and ligand-gated 
channels such as those activated by opened by GABA and glycine. The binding of the 
neurotransmitter glycine to the receptor opens the pore and allows for Cl- secretion. The glycine 
receptor, like most ion channels, is composed of several subunits that assemble to form a 
selective pore. The channel pore is formed at the center of the cluster that consists of both α and 
β subunits.  A variant containing only α-subunits of GlyR combine to form homopentameric 
pores that expressed functionality in Xenopus oocytes (Schmeiden et al., 1989).  The fact that a 
single M2 sequence can form a chloride channel made this an obvious choice for further 
investigations. 
 
 An Introduction to Cystic Fibrosis   
Epithelia, composed of numerous tightly packed cells, serve as barriers that employ 
diverse channels and transporters to regulate the movement of solutes and solvents into and 
between different body compartments. Epithelial barriers protect organs and the body as a whole 
from unregulated penetration of harmful substances and also serve to sustain the necessary 
concentrations of various chemicals within those compartments. Improper function of the 
channels that contribute to solute and solvent transport can lead to illness or death. 
Cystic fibrosis is a recessive autosomal genetic channelopathy (Becq, 2010); the result of 
dysfunctional CFTR, or cystic fibrosis transmembrane conductance regulator, which contributes 
to the permeation of anions across epithelial membranes (Zhang, 2000). CFTR is encoded by its 
eponymous gene, and is itself indirectly regulated by cyclic adenosine monophosphate (cAMP) 
(Sheppard and Welsh, 1999; Davis 2006). The protein is composed of two nucleotide-binding 
domains, two membrane-spanning domains, and a regulatory domain, which contains sites that 
can be phosphorylated by protein kinase A (Riordan, 2008; Devidas and Guggino, 1997; 
McCarty, 2000; Zhang et al., 2000). Protein kinase C has also been reported to modify CFTR 
function (Jia et al., 1997). CFTR is an adenosine triphosphate (ATP) binding cassette transporter, 
a member of a family of transmembrane proteins that use ATP as an energy source in carrying 
out their respective functions (Higgins, 1995). CFTR is the only member of this superfamily that 
acts as an ion channel, primarily serving to facilitate anion transport across epithelia throughout 
the body (Quinton, 1999; Davis 2006).  
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Mutations responsible for malfunctions in CFTR that lead to cystic fibrosis are 
categorized into five classes relative to their respective mechanisms of disruption (Pilewski and 
Frizzell, 1999). Classes 1 and 2 lead to disease across multiple organs, most notably pancreatic 
insufficiency, male infertility, bowel obstruction, and progressive lung disease (Rowntree and 
Harris, 2003). Class 1 comprises all mutations that result in abnormal biosynthesis and/or 
disrupted translation of CFTR. Class 2 contains mutations that affect the folding and trafficking 
of the protein. The most common mutation to CFTR, ΔF508, which represents a deletion of 
phenylalanine at position 508 of the protein, is a class 2 mutation. ΔF508 CFTR is recognized by 
the cell as a defective protein, and is endosomally degraded before it can form a channel in the 
cell membrane (Mall et al., 2004; Kopito, 1999; Pilewski and Frizzell, 1999). Class 3 is virtually 
indistinguishable from class 1 and class 2 type mutations with respect to its resulting symptoms 
in the lungs and pancreas (Pilewski and Frizzell, 1999; Rowntree and Harris, 2003). However, 
this class includes mutations that affect regulation of channel gating (Pilewski and Frizzell, 
1999) and is typified by the well-characterized G511D mutation. Classes 4 and 5 of CFTR-
disrupting mutations lead to partial function in CFTR channel activity at the cell membrane. 
With class 4 mutations, an otherwise normally developed CFTR protein forms a channel that 
exhibits decreased gating or transport ability of chloride relative to its fully-functional 
counterpart. Class 5 mutations characterize those that result in the alternative splicing of mRNA 
sequences, which leads to an alternate transcript, and therefore a reduction in expressed CFTR. 
Class 5 mutations can result in pancreatic disease and congenital bilateral absence of the vas 
deferens (CBAVD; Pilewski and Frizzell, 1999; Rowntree and Harris, 2003). 
Compromised CFTR function can cause a wide variety of maladies by way of insufficient 
ion transport in a number of corporeal systems, including the sweat glands, pancreas, and 
airways. Pulmonary disease is perhaps the most widely recognized symptom of cystic fibrosis 
that results from recurrent or chronic bacterial infection by Pseudomonas aeruginosa, 
Staphylococcus aureas, Burkholderia cepacia, and Haemophilis influenza (Rowe et al., 2006). 
These bacteria thrive in the thick, sticky mucus that accumulates due to reduced fluid secretion in 
the lungs and remains uncleared from the airways (Quinton, 1999; Planells-Cases and Jentsch, 
2009). Activation of nuclear factor kappa B by neutrophils and macrophages leads to 
inflammation and scarring, which is typical of the disease (Rowe et al., 2006). Furthermore, 
studies suggest also that inflammatory response regulation may be impaired by defective CFTR 
(Pilewski and Frizzell, 1999). The thick, viscous mucus that supports the infection is the result of 
leukocyte apoptosis and abnormal, dehydrated mucin glycoproteins that fail to fully unfold when 
secreted (Davis, 2006). Not only does the fluid on the surface of the airways aid in the hydration 
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of the system and facilitate the clearance of mucus, it also contains neutrophils and macrophages 
that help reduce infections (Tarran, 2004).  
In addition to lung infections and bronchiectasis, mutations of CFTR and dysfunctional 
CFTR protein can result in a wide range of symptoms, due in part to its role in regulating 
concentrations of Cl- and bicarbonate (HCO3-), and subsequently, concentrations of counter-ions 
and fluid volume. Normally Na+/K+-ATPase moves Na+ out of the cell from the basolateral 
membrane, creating a driving force for apical Na+ uptake. Adrenaline stimulates receptors that 
increase cellular cAMP, releasing sweat from the duct and increasing the uptake of extracellular 
salts. In CF epithelia, however, inadequate Cl- uptake leads to depolarization as sodium is still 
absorbed into the epithelium. This ultimately leads to a reduction in driving force for continued 
sodium absorption, resulting in the excess salt in human sweat, which serves as the basis of the 
common “sweat test” for CF (Ashcroft, 2000; Rowe et al., 2006). The transport of HCO3- can 
also be impacted by abnormal CFTR, through which it permeates, or indirectly by way of the 
effect of Cl- concentration imbalances on the Cl-/HCO3- exchange transporter present in the 
lungs and ducts of the pancreas (Kim and Steward, 2009). Impaired transport of Cl- in biological 
epithelia is a direct result of malfunctioning CFTR, and often results in abnormal or reduced 
fluid secretion (Welsh, 1987; Li et al., 1989, Anderson et al., 1992; Smith et al., 1994; Zhou et 
al., 2002).  
 
 Current Palliative Options and Experimental Therapies 
The majority of present therapies for cystic fibrosis are palliative in nature. Patients 
suffering from cystic fibrosis-related diabetes are generally given insulin to compensate for the 
resistance and decreased production of the hormone. Dietary supplements, such as Yasoo Health 
Inc’s compound, AquADEKs® restore necessary vitamins deficient in those with the disease and 
have been shown to reduce several cystic fibrosis associated pulmonary symptoms (Sagel et al., 
2011). The USFDA has approved several therapies for the replacement of pancreatic enzymes, 
which aid in vitamin and nutrient absorption. These include Zennen® (Eurand Pharmaceuticals), 
Creon® (Abbott Laboratories) and Pancreaze™ (Ortho-McNeil Pharmaceutical). Several others 
are still in the pipeline, but require additional clinical trials for approval (Lowry, 2011). Insulin 
supplements are used to restore function for those who suffer from cystic fibrosis related 
diabetes.   
Antibiotics and anti-infectives such as Aztreonam-based Cayston® (Gilead Sciences), 
tobramycin-based TOBI® are used to target Pseudomonas aeruginosa, a common bacteria in CF 
airways, and have been reported to improve lung function (Cheer et al., 2003). Antibiotics can be 
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administered via a wide range of delivery systems (Gibson et al., 2003). Azithromycin (Pfizer, 
Inc.) has also been explored as an antibiotic for CF patients. While it initially showed great 
promise in reducing infections of Pseudomonas aeruginosa (Saiman et al., 2003), more recent 
studies suggest that prolonged use may contribute to heart disease (Ray et al., 2012) and chronic 
infection by other bacteria (Renna et al., 2011). Anti-inflammatories fight the pulmonary 
inflammation that leads to fibrosis and a decrease in lung function in CF patients. Twice-daily 
ibuprofen was shown to slow the rate of deterioration of the pulmonary systems of those with CF 
(Konstan et al., 1995). KB001 (Kalobios Pharmaceuticals) moderates virulence factors of 
Pseudomonas aeruginosa that play a role in inflammation (Baer et al., 2008).  
A number of approaches target viscous pulmonary mucus to address CF symptoms. 
These include airway rehydrating agents, which work to flush extant mucus in the lungs and 
promote expectoration (Pettit and Johnson, 2011) and mucolytics, which reduce mucosal 
viscosity. Dornase alfa-based Pulmozyme® (Genentech) is a recombinant human 
deoxyribonuclease, which acts to decompose mucus-thickening DNA, and has been shown to 
reduce infection rates and increase lung function in those with CF (Fuchs et al., 1994); Moli1901 
(Lantibio Pharmaceuticals) works by Cl- conductance via alternate channels to improve lung 
function (Grasemann et al., 2007); and GS9411 (Gilead Sciences) acts to inhibit the absorption 
of sodium via epithelial Na+ channels (ENaC) (Sears et al., 2011; clinicaltrials.gov). A mist of 
nebulized hypertonic saline was shown to improve pulmonary function, presumably by 
safeguarding healthier airways from continued infection (Elkins et al., 2006; Donaldson et al., 
2006), and inhaled mannitol acts by osmosis to increase airway hydration (Jaques et al., 2008; 
Bilton et al., 2011).  
 Alternative and Experimental Therapies 
Several experimental therapies demonstrate potential as alternatives to palliative 
treatment and aim to replace dysfunctional CFTR or restore function to mutated forms. 
PLASmin® compacted DNA (Copernicus Pharmaceuticals) is a gene therapy that avoids some 
common difficulties presented by viral vectors through the use of polycation-condensed DNA 
(which condenses DNA by roughly 1000x), and is capable of membrane permeation (Chen et al., 
2007). Intra-nasal application showed tolerability and increased function, but evidence of gene 
expression was absent (Konstan et al., 2004). 
Ivacaftor (Kalydeco; VX-770; Vertex Pharmaceuticals) is noted as one of the first FDA-
approved non-palliative therapies for CF. VX-770 decreases the high closing rate of CFTR 
channels resulting from the G551D mutation. VX-770’s potentiating action requires no ATP, but 
depends on phosphorylation (Eckford et al., 2012). It has also been shown to improve pulmonary 
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function and normalize Cl- levels in human sweat (Sheridan, 2011). Ivacaftor has also been used 
in combination with Lumicaftor (VX-809; Vertex Pharmaceuticals), which corrects trafficking of 
CFTR in CF patients with common mutation ΔF508 (Thibodeau et al., 2010). As with the 
G551D mutation, VX-770 maintains the pore’s open conformation (Pollack, 2011; and 
http://investors.vrtx.com/releasedetail.cfm?releaseid= 583683). This combination therapeutic has 
recently passed all clinical trials, and Vertex will be submitting a new drug application to the 
USFDA by the end of the year for potential approval in 2015 
(http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185).  
 Small-molecule therapeutic, Ataluren® (PTC Therapeutics) restores full-length CFTR 
from those harboring harboring nonsense mutations. Clinical trials demonstrated increased ion 
transport in nasal epithelia (Wilschanski et al., 2011; and http://www.ptcbio.com/ 
3.1.1_genetic_disorders.aspx), but there is debate about the credibility of the assay in these trials 
(Auld et al., 2010; Peltz et al., 2009). 
 
 Ion Channel Replacement Therapy 
The subsequent experiments explore what is believed to be a more straightforward and 
optimizable approach to CFG therapy: the use of synthetic peptide channels as a substitute for 
naturally produced CFTR. This method of ion channel replacement therapy avoids many pitfalls 
of gene therapy, including difficulty with viral vectors, transformation, subsequent functionality 
of the protein. The aim is to develop easily deliverable, anion selective pore-forming peptides 
with maximal ability to regulate ion flow and minimal antigenic effects.  
This laboratory’s aim has long been the production and optimization of synthetic peptides 
capable of forming ion-penetrable pores modeled after an ion channel found in the glycine 
receptor of the spinal cord. These peptides, classified as M2GlyR peptides, are modeled after the 
second transmembrane segment (M2) of the glycine receptor alpha-subunit (GlyR), which was 
initially characterized by Reddy et al. (1993). Those studies demonstrated anion-selective 
transport across lipid membranes, showing similarity to the native Glycine receptor. This model 
has served as the foundation for subsequent studies on various permutations of the original 
M2GlyR sequence (PARVGLGITTVLTMTTQSSGSRA; from amino acid 250-272 of GlyR). 
Further studies explored the effects of addition, elimination, and substitution of amino acids in 
the sequence on structure, channel-forming ability, and subsequent ion conduction. Numerous 
CFTR transmembrane segments (M1-6; M10-12) have been implicated as playing a role in the 
formation of the Cl- selective pore (Montal, et al., 1994; Zhang et al., 2000; Linsdell, 2006), and 
the channel’s selectivity filter is associated with the M6 segment (Zhou et al., 2002; Beck et al., 
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2008; Alexander et al., 2009). The relative simplicity, yet similar conductive ability of M2GlyR 
makes it an optimal platform sequence from which synthetic peptides might be modeled.  
The beauty of this approach lies in its direct, yet relatively simple methodology. Unlike 
palliative options, which merely treat the symptoms of the disease, our peptides have the 
capacity to restore ion transport across epithelia by delivery (most effectively via aerosolized 
inhalants) directly into the airways, allowing the peptide to insert in the apical membrane and 
auto-assemble to form de novo anion selective channels. In addition, as discussed above, unlike 
gene therapy and similar methods, this method circumvents many of the difficulties in associated 
with DNA delivery and protein expression. 
An optimized channel-forming peptide will exhibit a number of distinct characteristics. 
Peptides should exhibit solubility in aqueous solution and retain the capacity to form anion 
conducting channels in epithelial membranes utilizing as little peptide as possible to achieve 
desired ends. One facet of this faculty requires that the majority of peptide in solution should 
remain in monomeric form. Peptides that bind cellular membranes in monomeric form have been 
shown to form functional channels. This factor also contributes to the ability to accurately 
calculate requisite quantity and concentration of the effectively binding peptide for therapeutic 
use. Previous studies demonstrated that M2GlyR peptides are generally well-tolerated by mice, 
eliciting no detectible detectable antigenic effects (Van Ginkel et al., 2008). Because natural 
electrochemical gradients across cell membranes serve as the driving force for channel 
permeation, there is little risk of excess secretion.  
 M2GlyR-altered sequences 
Beginning with the M2GlyR sequence, single and multiple amino acid substitutions were 
explored to improve the properties of the peptide as a potential therapeutic agent.  Initial studies 
with M2GlyR sequences explored both monomeric and tetrarameric templated structures 
following previous general protocols (T4-M2GlyR) (Mutter et al., 1989; Iwamoto et al., 1994), 
but the latter was ultimately rejected in favor of the more efficiently synthesized and purified 
monomer, which showed an increase in short circuit current (Isc) in Manin-Darby canine kidney 
(MDCK) epithelial monolayers. However, the change in Isc was not immediate and occurred only 
in a percentage of all monolayers tested. Furthermore, low solubility and uncontrolled orientation 
of inserted peptide led to the exploration of modified sequences.  
In an attempt to better control solubility and insertional orientation, second-generation 
sequences incorporated terminal oligo-lysine residues. C-terminal pentameric-lysine adducted 
variants demonstrated the most notable solubility increase, while tetrameric-lysine adducts to 
either terminus yielded the most optimal balance in solubility and increase in Isc (Tomich et al., 
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1998). Furthermore, the C-terminal lysine adducted peptide allowed for the same transmembrane 
orientation as the corresponding segment in the native glycine receptor, and provided stability in 
supramolecular assembly of channel formation.   
Later studies demonstrated that the modulation of K+ secretion via Ca2+-dependent 
channels in the basolateral membrane of epithelia affected the transport elicited by apically-
inserted CK4-M2GlyR in T84 cells. K+-channel inhibition by clotrimazole and charybdotoxin 
resulted in a reduced Isc elicited by the peptide, whereas activators, such as 1-ethyl-2-
benzimidazolinone (1-EBIO) amplified the Isc response to equal concentrations of peptide, 
suggesting coordination between K+ efflux across the basolateral membrane and fluid as a 
consequence of Cl- release. (Wallace et al., 2000). In the presence of 1-EBIO, ion transport by N-
terminal lysine-adducted sequences was significantly larger than that of CK4 peptides at identical 
concentrations (Broughman et al., 2001; Wallace et al., 1997), and led to the exploration of NK4-
M2GlyR as the lead peptide in the class to develop as a potential therapeutic. Additional studies 
explored the effect of CK4-M2GlyR and NK4-M2GlyR on nasal potential difference (PD) in 
ΔF508 transgenic mice. Data suggested that pre-exposing murine nasal epithelia to one of the 
two tetralysine-adducted peptides led to near normalization of Cl- and fluid secretion relative to 
CF mice in control groups (in which the expected response was null) and those without treatment 
(Tomich, Unpublished results).  
However, higher Isc at low concentration was not the sole determining factor in selecting 
a lead sequence and in many regards NK4-M2GlyR was observed to be suboptimal. Chemical 
cross-linking, nuclear magnetic resonance (NMR) imaging and computer modeling studies were 
used to examine the effects of different points of adduction of poly-lysine residues. As 
hydrophobic residues tend to condense together in solution, aggregation can become problematic 
with higher peptide concentrations. Ideally, as discussed previously, the majority of the peptide 
should be monomeric in aqueous solution, without sacrifice of its channel formation and 
conductance properties. In order to study solution aggregation, bis [sulfosuccinimidyl] suberate 
(BS3) was used as a cross-linking reagent to lock aggregates into oligomeric form through the 
use of its free-amine binding molecules. Silver-stained sodium dodecyl sulfate polyacrylamine 
gel electrophoresis (SDS-PAGE) gels were then used to visualize molecular aggregation in 
solution (Broughman et al., 2002b). These studies determined that CK4-M2GlyR sequences 
exhibit lower aggregation in solution relative to their NK4 counterparts, with predominant 
aggregates being those of trimmers and dimers, with much of the peptide remaining monomeric. 
NK4-M2GlyR, on the other had, demonstrated considerably greater aggregation, showing 
oligomers increasing from non-aggregated peptide through 20-mers, as shown in fig. 1.1. 
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Figure 1.1: Association profile of CK4- and NK4-M2GlyR p27 
tricine polyacrylamide gel, silver stained, of NK4-M2GlyR and CK4-M2GlyR peptides. Lanes 1 
and 10 hold standards for molecular weight; lanes 2– 4, NK4-M2GlyR treated with cross-linking 
reagent in 40-fold excess (100, 200, and 300 µM, respectively); lane 5, untreated NK4-M2GlyR 
boiled in sample buffer containing SDS; lanes 6–8, CK4- treated with cross-linking reagent in 
40-fold excess (100, 200, and 300 µM, respectively); lane 9, untreated CK4-M2GlyR, boiled in 
sample buffer containing SDS (reprinted with permission from Broughman et al., copyright 
2002b, American Chemical Society). 
 
Further studies sought to determine residues of NK4-M2GlyR that contributed to 
aggregation of the peptide in solution. Both NK4-M2GlyR and CK4-M2GlyR were truncated at 
various points and results indicated that truncation of NK4-M2GlyR’s five C-terminal residues 
(SGSRA) decreased aqueous peptide aggregation (fig. 1.2) without inducing a notable reduction 
in Isc (fig. 1.3). In contrast, there was little change in aggregation of CK4-M2GlyR when residues 
were truncated from the N-terminal end, but there was a negative effect on ion transport. 
Ultimately, a truncated form of NK4-M2GlyR, p22, was adopted as the lead peptide for further 
study. Furthermore, this shorter peptide was more easily synthesized due to a reduced number of 
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amino acid additions and therefore more cost-effective to manufacture than any of its 
counterparts.  
 
Figure 1.2: Cross-Linked M2GlyR Truncated Peptides  
Tricine polyacrylamide gel, visualized with silver stain, of cross-linking patterns for truncated 
CK4- M2GlyR and NK4-M2GlyR. X-axis demonstrates truncation points of the given peptide 
e.g. p27, truncated at 27 residues, and so on). All samples were treated with a 40-fold excess of 
crosslinking reagent (Broughman et al., 2002b) 
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Figure 1.3: Activity of Truncated M2GlyR Segments NK4- and CK4-M2GlyR 
Isc given by truncated and full-length peptide sequences of NK4- and CK4-M2GlyR peptides at 
500 µM in MDCK monolayers. Symbols represent mean and standard error of three to seven 
observations. (Broughman et al., 2002b) 
 
In eliminating several hydrophilic residues from NK4-M2GlyR to make its p-22 truncated 
sequence, the overall hydrophobicity of the peptide was increased, making it less soluble in 
solution (Wimley and White, 2000; Jayasinghe et al., 2001). This truncation included the 
elimination of the C-terminal arginine in the truncated NK4-M2GlyR-p22 sequence, which, as 
suggested by previous NMR studies on native sequence M2, plays a role in defining the 
transmembrane domain due to its propensity to lie at the membrane’s lipid/water interface (Tang 
et al., 2002; Yushmanov et al., 2003; Vogt et al., 2000; Harzer and Bechinger, 2000; Mitaku et 
al., 2002). Subsequent studies were undertaken to explore whether an arginine insertion at the C-
terminal end of the truncated NK4-M2GlyR-p22 might affect solubility, transmembrane 
positioning and channel conductance (Shank et al., 2006). Results indicated that this arginine 
substitution at position 19 and beyond dramatically increased aqueous solubility without 
drastically affecting aggregation patterns or Isc values relative to the parent p22 sequence.  
According to several studies, not only arginine, but also tryptophan (Trp; W) has a 
demonstrated preference to position itself at the lipid/water interface and may therefore play a 
role in defining transmembrane domains (Braun and von Heijne, 1999; Mall et al., 2004; 
Demmers et al., 2001; de Planque et al., 2003; Granseth et al., 2005; van der Wel et al., 2007; 
Hong et al., 2007). A more clearly defined boundary for the transmembrane domain limits 
peptide mobility within the membrane, restricting its position and reducing deviations in 
angulation of peptides forming the channel and thereby reducing degrees of freedom. Studies 
into the substitution of the C-terminal serine of NK4-M2GlyR-p22 with a Trp demonstrated a 
notable change in IMAX (maximal short-circuit current observed), K½ (concentration at ½ IMAX, and 
Hill coefficient as given by the Hill equation. Though IMAX elicited was reduced somewhat from 
the parent sequence and similar truncated forms (Broughman et al., 2002b), a significant increase 
in Hill coefficient and decrease in K½ suggests that such Trp-substituted peptides are notably 
more effective than their unsubstituted counterparts at much lower concentrations (fig. 1.4). 
Cross-linking studies indicated that the S22W form (in which the serine at position 22 is replaced 
with a Trp residue) was primarily monomeric (Cook et al, 2004). As a bonus, the addition of the 
280nm light-absorbing Trp allowed for more accurate concentration determinations via 
spectrophotometry.   
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Figure 1.4: Peptide concentration dependence on ISC in MDCK monolayers 
Concentration-dependence of Isc by NK4-M2GlyR-p22 derived peptides with Trp and Arg 
substitutions on MDCK monolayers. Symbols represent the mean and standard error of 6 or 
greater observations for each concentration tested. Solid lines represent the best fit of a modified 
Hill equation to each data set, given by ΔIsc = (ΔIMAX*xn)/(EC50n + xn) (further explained in 
Chapter 2). Letters indicate the final four amino acids for the peptide given by each plot, and is 
given along with the number code for each given sequence. (Broughman et al., 2002) 
 
 The Trp-substituted peptide’s ability to resist solution aggregation is an ideal endpoint in 
the development of a potential therapeutic. As discussed previously, the ability to accurately 
calculate the concentration of monomeric peptide available for channel formation and utilize as 
much of the delivered peptide as possible results in lower dosages, minimized excess, and 
confers economic advantages.  
The reintroduction of a positively-charged arginine residue in addition to the tryptophan 
substitution was hypothesized to affect anion conductance. Further experiments explored the 
effects of residue substitutions by phenylalanine and tyrosine in place of Trp, and found Trp to 
remain the optimal aromatic residue for promoting channel assembly. Results indicated that 
while NK4-M2GlyR-p22 T19R, S22W and NK4-M2GlyR-p22 Q21W, S22R demonstrated 
optimal decreases in K½, the likely membrane-thinning effects of a C-terminal arginine led its 
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alternate, NK4-M2GlyR-p22 T19R, S22W to surface as a lead compound for future study (Cook 
et al, 2004). 
While Trp and Arg-substituted NK4-M2GlyR p-22 sequences have demonstrated a great 
deal of promise, relatively reduced aggregation in CK4-M2GlyR also suggested that the tetra-lysl 
adduct to the C-terminus likely plays a role in countering the nucleation effect of the residues 
truncated in NK4-M2GlyR-p22. Despite its apparent advantages in other endpoints, NK4-
M2GlyR is notably less soluble than its CK4 counterpart in aqueous solution. In an attempt to 
determine whether CK4-M2GlyR could elicit similar optimization in kinetic parameters, 
aggregation, and selectivity when substituted with a pore-defining Trp residue, further study, as 
presented in the following work, explores whether any of several subsequent Trp-substituted 
CK4-M2GlyR sequences might, when explored and modified, warrant further investigation and 
perhaps demonstrate similar promise as a therapeutic agent for cystic fibrosis.  
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Chapter 2 - Materials and Methods 
 Syntheses 
NC-1007 (CK4-M2GlyR) and its related tryptophan-substituted peptides were constructed 
using N-α-Fmoc protected amino acids (AnaSpec Inc., San Jose, CA) on CLEAR amide resin 
(0.3 mmol g–1; Peptides International, Louisville, KY) scaled to 0.5 mmol per synthesis.  All 
amino acids were double-coupled. Piperidine (99%) was used for the Fmoc deprotection step, 
and a solution of 0.225 M for both O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyl-uronium 
hexafluorophosphate (HBTU) and hydroxybenzotriazole (HOBt) solubilized in 
dimethylformamide (DMF) was used for the activation step. For capping, 19 ml acetic 
anhydride, 9 ml N, N-diisopropylethylamine (DIEA), and 6 ml of 1 M HOBt in N-Methyl-2-
pyrrolidone (NMP) were combined and further diluted with NMP to 400 ml. Chemicals used 
were obtained as follows: DMF, NMP, and DIEA from American Bioanalytical, Inc. (Natick, 
MA), and HBTU and HOBt from Anaspec. Reactions were conducted using 9-
fluorenylmethoxycarbonyl (Fmoc) chemistries (Carpino, 1972; Fields, 1990) on a 431A peptide 
synthesizer (Applied Biosystems, Foster City, CA).  
 
 Cleavage, Deprotection and Characterization 
The completed peptide bound to resin was suspended in 10 mL of 95% trifluoroacetic 
acid (TFA) and 5% distilled water and left to set at room temperature for three hours to cleave 
the peptide from the support and deprotect all side-chain protecting groups (King, 1990).  The 
cleaved peptide was then washed with 30 mL diethyl ether four times, the first of which 
precipitated the peptide. After being washed with diethyl ether, the precipitated peptide was 
reconstituted in distilled water, and subsequently extracted by precipitating twice and a final 
wash with diethyl ether. The peptide was then freeze dried to be used for subsequent 
experiments.  A portion of the dried material was dissolved in 50% trifluoroethanol/water 
solution and analyzed by Mass Spectrometry using CHCA matrix on a Bruker Ultraflex II 
MALDI TOF/TOF (Bruker Daltronics, Billerica, MA) 
 
 
 Concentration Determination 
For all studies, peptide concentrations were determined spectrophotometrically to a 
precision of 0.05 µM using Beer’s Law: A = εbc (where A represents absorbance value as given 
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by the spectral report, ε is molar extinction coefficient of a given residue or residues in L mol-1 
cm-1, b represents the path length in cm, and c is the peptide molar concentration). The 
substituted tryptophan, present in four of the five studied peptides (those altered from the native 
sequence) provided the chromophore for this application. Because of its aromatic side-chain, a 
Trp residue absorbs wavelengths in the electromagnetic spectrum at 280 nm, and has a molar 
absorptivity of 5540 (Edelhoch, 1967; Mach et al., 1992). Absorbance was measured at 280 nm 
using a Varian Cary WinUV 50 Bio UV spectrophotometer (Palo Alto, CA). Stock samples were 
diluted by 20-fold for determination, then adjusted to the desired concentrations. In the case of 
the Trp-free native NC1007, a Bradford Colorimetric Protein Assay kit (Thermo Fisher 
Scientific, Inc., Rockford, Illinois) was used for concentration determination, the Trp-containing 
peptide NC1007 G20W was used as a reference for the assay. 
 
 Circular Dichroism 
In order to evaluate the secondary structure of the peptide NC-1007 (CK4-M2GlyR) and 
its Trp-substituted analogs, circular dichroism (CD) studies were undertaken to determine 
whether the peptide maintained its characteristic alpha-helical structure  in both 50% 
trifluoroethanol (TFE) solution. Prior to characterization, the system was first blanked with 50% 
TFE solution in which the peptide was to be profiled, absent the peptide itself. This spectra was 
subtracted from subsequent spectra.  
Peptides were first characterized at 100 µM dissolved in 50% TFE in order to record the 
spectra. TFE acts by stabilizing peptide secondary through the tight association of the TFE 
molecules with the peptide, displacing water and eliminating the ability of the peptide to form 
hydrogen bonds with water, thus promoting hydrogen bonding within the peptide, without 
affecting intra-molecular interaction of nonpolar residues (Roccatano et al., 2002). 
Spectropolarimeter recordings were performed on a J-720 instrument (Jasco USA; Eaton, MD), 
and samples were placed in a 1.0 mm cylindrical quartz cuvette. Each recording is a machine-
calculated average of five scans per sample. Spectra were assessed from 260 to 190 nm 
wavelengths at a rate of 20 nm per minute with a 0.2 nm step resolution and 1.0 nm spectral 
bandwidth and data analysis was performed with software included. Data were recorded in 
observed ellipticity (θ, in millidegrees, mdeg). However, accounting for peptide concentration, 
path length, and residue number, mean ellipticity per residue can be calculated using the 
following equation: 
 
[θ] = (100* θ)/([x]n*l)  
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Where [θ] is the mean residue ellipticity (deg cm2 decimole-1); θ is the observed ellipticity value 
recorded by the instrument (mdeg); [x], peptide molar concentration; n, total number of amino 
acid residues comprising the peptide; and l is the path length through the cuvette (cm) (Myers et 
al., 1997). 
 
 Cell Culture 
Madin-Darby canine kidney (MDCK) epithelial cells, were originally the generous gift of Dr. 
Lawrence Sullivan (University of Kansas Medical Center, Kansas City, KS). Cells with passage 
numbers from 26-41 were cultured on solid substrate culture flasks (T25 Cellstar 25 cm2 flasks; 
Frickenhausen, Germany). Culture medium was composed of a 1:1 ratio of Dulbecco’s Modified 
Eagle Medium and Ham’s F-12 nutrient mixture (F-12; Invitrogen, Carlsbad, CA), with the 
addition of 5% heat-inactivated fetal bovine serum (FBS; BioWhittaker, Walkersville, MD), and 
1% penicillin/streptomycin mixture (Life Technologies, Invitrogen). FBS contains a number of 
hormones and nutrients as well as attachment, growth and spreading factors that promote cell 
growth and proliferation (Gstraunthaler, 2003). The penicillin/streptomycin mixture protects the 
culture from gram-positive and gram-negative bacterial contamination by disrupting cell wall 
turnover (penicillin; Doyle et al, 1988), and inhibiting bacterial protein synthesis by binding to 
bacterial ribosomes, (streptomycin; Cox et al., 1964). 
After seeding, MDCK cells were left to proliferate in a 37° C incubator set to contain 5% 
carbon dioxide. T25 culture flasks that demonstrated 70-90% cellular confluence (roughly four 
days post-seeding) were subcultured into T25 flasks for further growth or on permeable supports 
(Snapwell; Costar, Cambridge, MA). Transfer of cells from a given flask was conducted by 
aspirating medium and rinsing cells with a solution of phosphate-buffered saline (PBS: 137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4). After aspirating the PBS, 0.2 mL of 
0.25% trypsin, containing 2.6 mM ethylenediaminetetraacetic acid (EDTA; which acts to break 
inter-cellular adherence by interrupting the junction of calcium dependent cadherins which form 
adheren junctions between cells). Remaining solution was immediately aspirated and cells were 
placed in a 37° C incubator until dissociation was largely complete. Dissociated cells could then 
be re-seeded into flasks or on permeable supports as mentioned above. Media were refreshed 
every other day and experiments were conducted within one day of feeding. Permeable supports 
prepared for Ussing experiments were cultured for a minimum of two weeks (allowed to reach a 
confluent density of approximately 1*106 cells per well) before use. 
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                       Transepithelial Electrical Measurements 
In order to evaluate the propensity of each given peptide to form pores capable of 
supporting transcellular ion transport across the epithelial cell membranes, electrical currents 
were recorded using a modified Ussing chamber (Navicyte DCV9; San Diego, California) were 
vertically mounted into vertical diffusion chambers and exposed bilaterally to 10 ml (5 ml each 
apically and basolaterally) of freshly made Ringer solution (120 mM NaCl, 25 mM NaHCO3, 3.3 
mM KH2PO4, 0.8 mM K2HPO4, 1.2 MgCl2, 1.2 mM CaCl2; Misfeldt, 1976; Hille, 2001). All 
chemicals used in the production of Ringer solution were acquired from Sigma-Aldrich (St. 
Louis, MO). Chambers were maintained at physiological temperature (37°) and aerated with a 
gas mixture of 5% CO2 and 95% O2 in order to provide solution mixing in addition to 
maintaining pH. Each of six MDCK epithelial monolayers, all grown on the same permeable 
supports as discussed above were measured their initial transepithelial resistance. Monolayers 
with initial resistance values of less than 200 Ohms cm2 were excluded from further testing. 
 Drugs added during the course of the assay included 1-ethyl-2-benzimidazolinone (1-
EBIO; Acros Organics, Morris Plains, New NJ) in dimethyl sulfoxide (DMSO) from Sigma 
Chemical. Forskolin (Coleus forskohlii) was acquired from Calbiochem (La Jolla, CA), and 
prepared at 10 mM in ethanol.  
 Transepithelial voltage across the monolayer was clamped at zero using a 558C-model 
voltage clamp apparatus made by the University of Iowa’s Department of Bioengineering (Iowa 
City, IA), and Isc was recorded continually (Broughman et al., 2001; 2004). Monolayers were 
exposed to a 5 second 2 mV bipolar pulse between clamped intervals of 90 seconds. Data were 
aquired at 1 Hz by (Aqknowledge software, version 3.2.6; BIOPAC Systems, Santa Barbara, 
CA) with an MP100A-CEinterface. 
 During each experiment, each of the six chambers was allowed to establish stable 
parameters, and then was exposed to 1-EBIO (100 µM) to maximize driving force for anion 
secretion. EBIO hyperpolarizes the epithelia through the activation of Ca2+ dependent K+ 
channels in the basolateral cell membrane (Devor, 1996). Although 1-EBIO is capable of 
stimulating endogenous CFTR, concentrations used in study were significantly lower than those 
required to increase CFTR channel activity. After establishing a stable baseline Isc , one of five 
peptide concentrations (30 µM, 60 µM, 100 µM, 200 µM, and 300 µM) or a control (300 µL 
H2O) was added apically to each of the six chambers. After recording the changes in Isc for a 
prescribed period, forskolin (1 µM) was added to test for cell viability. Forskolin activates 
adenylate cyclase, an enzyme responsible for the conversion of adenosine triphosphate (ATP) 
into cyclic adenosine monophosphate (cAMP).  Protein kinase A, a phosphorylating agent which 
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indirectly activates CFTR, increases the secretion of any remaining intracellular Cl- as well as 
extracellular uptake through the activation of the Na+/K+/Cl- cotransporter, inducing an 
observable increase in Isc for intact cells (Carlin et al. 2006; Andrea-Winslow et al., 2001). 
 Analysis of Isc Data 
In order to evaluate the propensity of each peptide to form functional anion-selective 
channels, ion transport across epithelial cell membrane were analyzed using Microsoft Excel 
software (Redman, WA). Each data point represents the mean peak change in Isc from baseline 
(post-EBIO) elicited by each peptide at each concentration from a minimum of five independent 
observations, where vertical bars represent the standard error of the mean (SEM). Statistical 
significance was defined relative to a type I error probability of 0.05 or less, as determined via 
Student’s t-test or analysis of variance (ANOVA) assessments in Microsoft Excel. 
 
Lines shown represent the best fit of a modified Hill equation to the data points given:  
 
ΔIsc = (ΔImax*xn)/(EC50n + xn), 
 
   
In which EC50 is the peptide concentration at which 50% of maximal Isc is attained; x is the 
concentration of peptide; and n is the Hill coefficient. In each case, the fit was constrained  
and n represents the Hill coefficient. In optimizing the fit to the data sets, Imax was constrained to 
a maximum of the mean value for the maximal peptide concentration observed (300 µM) + one 
standard deviation of that data set.  
 
 Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
Studies 
Lyophilized stock peptide was dissolved in 100 µl trifluoroethanol and diluted with 100 
µl of ultrapure deionized water for a final concentration of approximately 3 mg/ml in a solution 
of 50% TFE. The peptide was assessed by HPLC (System Gold HPLC; Beckman Instruments, 
Fullerton, CA) using a reverse-phase C-18 column (Phenomenex, Torrance, CA). Two solvents 
were gradated with one another to elute peptide from the column: Solvent A, composed of 0.1% 
trifluoroacetic acid (TFA) in ultrapure deionized water, and solvent B, consisting of 0.1% TFA 
in 90% acetonitrile, 10% water. Successive gradation, sustention, and re-equilibration 
characterize the course of the HPLC profile. Free salts elute first from the system with peptides 
remaining bound to the column’s solid phase during the five-minute stable flow of 10% Solvent 
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B and 90% Solvent A. Next, the peptide was eluted during the course of a linearly increasing 30-
minute graduation of the ratio of solvent B (TFA in ultrapure water) to solvent A (acetonitrile) 
from 10:90 to 90:10 during which peptides are generally released with the mobile phase near the 
20-minute mark. After the gradient stage, the end ratio of 90:10 solvent B: solvent A was 
maintained for five minutes to elute any remaining substances in the column. Elution was 
monitored by the UV detector at 220 nm 
  UV/Vis Spectrometry 
Absorbance spectra were employed to determining whether the peptide demonstrated a 
patterned violet shift characteristic of tryptophan (standard absorbance, 280 nm) protected within 
the hydrophobic environment of the aggregate for peptides (one each in which the substituted 
tryptophan was located within the hydrophobic or hydrophilic faces of the helix as determined by 
helix wheel modeling described in the next chapter) as compared to that of the free amino acid 
from Sigma-Aldrich. Samples of NC1007 S18W and NC1007 G20W (selected for the clearly 
defined location of the w-substitution in the hydrophobic and hydrophilic regions, respectively), 
as well as free tryptophan were prepared (5 mM in water) and profiled from 200 to 400 nm at a 
rate of 300 nm/min using a Varian Cary WinUV 50 Bio Ultraviolet/Visible spectrophotometer 
(Palo Alto, CA).  
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Chapter 4 - Results and Discussion 
 Characterization 
The purpose of the following studies was to assess whether alterations to the CK4-
M2GlyR peptide sequence, initially modeled after the second transmembrane segment of the 
spinal cord glycine receptor, via the sequential substitution of a Trp residue for C-terminal 
residues would affect secondary structure, solution aggregation, channel formation, and ion 
permselectivity.  
The peptides are denoted as derivatives of the NC-1007 sequence.  The control and 
modified sequences, with the substituted Trp in bold typeface are shown in Table 4.1 along with 
molecular weights.  These positions were selected with the hypothesis that the added Trp would 
serve as the interfacial residue for the C-terminal portion of the peptide. Previous work showed 
that Trp substitutions in N-K4-M2GlyR eliminated solution aggregation (Broughman et al., 
2002). Thus we anticipate a similar effect for one or more of the peptides prepared in this study.     
 
Peptide Conventional 
Name 
Sequence Molecular 
Mass (Da) 
CK4-M2GlyR- 
 
NC-1007  
 
PARVGLGITTVLTMTTQSSGSRAKKKK 2815.6 
CK4-M2GlyR-
S18W 
NC1007  
S18W 
PARVGLGITTVLTMTTQWSGSRAKKKK 2914.6 
CK4-M2GlyR-
S19W 
NC1007  
S19-W 
PARVGLGITTVLTMTTQSWGSRAKKKK 2914.6 
CK4-M2GlyR-
G20W 
NC-1007 
G20W 
PARVGLGITTVLTMTTQSSWSRAKKKK 2944.6 
CK4-M2GlyR-
S21W 
NC1007  
S21W 
PARVGLGITTVLTMTTQSSGWRAKKKK 2914.6 
 
Table 4.1 Conventional name, sequence, and molecular mass of experimental w-substituted 
variants of NC1007 
 
 The sequence in which the C-terminal serine21 was substituted with Trp posed the most 
abnormal behavior in several aspects, and had to be synthesized multiple times to obtain an 
effective batch of the proper sequence. Arginine-containing sequences are often pose difficulties 
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in synthesis due to poor coupling efficiencies of bulky amino acids that are added immediately 
after the arginine.  This is true in the case of the S21W sequence.  It is important to note that 
peptide synthesis occurs in the C- to N- direction so in the case of S21W the tryptophan is added 
after the arginine. 
After synthesis, peptides were characterized by MALDI-TOF spectrometry. Results are 
shown in Fig. 4.1.  In all of the MS tracing the desired product is observed for all of the 
syntheses as well as a number of other peaks generally of lower mass. Due to differences in 
moving the different components of the synthetic mixture into the gas phase this method is not 
quantifiable. Peak heights bear no relationship to relative concentrations, and unlabeled peaks are 
remnants of failed sequences, commonly those with amino acid deletions. 
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Figure 4.1 (A-E) MALDI-TOF spectral profiles for experimental peptides 
A: NC-1007, MW 2815.1 Da; B: NC-1007 S18W, MW 2917.2 Da; C: NC-1007 S19W, MW 
2920.0 Da; D: NC-1007 G20W, MW 2944.9 Da; E: NC-1007 S21W, MW 2914.7 Da 
X-axis indicates mass/charge ratio, and Y-axis indicates intensity, in arbitrary units (x104). 
 Circular Dichroism 
Circular dichroism (CD) studies were undertaken to determine whether the Trp-
substituted peptides maintained characteristic alpha-helical structure both in solution. After 
determination of effective synthesis by MALDI-TOF spectrometry, peptides were reconstituted 
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at 100 µM in 50% TFE for the CD structural determination experiments. All peptides, including 
NC-1007 S21W adopted α-helical conformations both in micelles and in solution as judged by 
the presence of characteristic minima at approximately 222 and 208 nm. TFE acts to stabilize 
secondary structure by hydrophobic interaction, preventing the peptide from forming inter-
peptidyl hydrogen bonds, and promoting intra-peptide bonding. Shown in Fig. 4.2. are data 
presented in mean molar residue ellipticity versus wavelength. From these results it is apparent 
that the introduction of the Trp residues does not affect the ability of the peptides to adopt a 
characteristic helical structure in membrane-like environments. Previous studies have suggested 
that peptides that fail to form helical structures in TFE also were ineffective at stimulating Isc. 
(Broughman, 2002)   
 
 
Figure 4.2: Circular Dichroism profiles of NC1007 W-substituted peptides 
Spectral profiles indicate characteristic α-helical structure with local minima at around 208 and 
220 nm at 100 µM in 50%TFE  
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Measurements of ISC were used to determine the concentration-dependent effects of Trp-
substituted NC-1007 sequences on ion transport. After establishing a consistent baseline, cells 
were exposed to 1-EBIO, and allowed to achieve a new stable baseline. ISC was recorded for the 
EBIO treated monolayers immediately prior to peptide exposure. 1-EBIO works by stimulating 
potassium (K+) channels in the basolateral membrane. The resultant movement of this positively 
charged ion acts to further hyperpolarize the cell, stimulating increased flux of Cl- by amplifying 
electrochemical driving force for anion secretion, and therefore, the measured response (Devor, 
1996; Broughman et al., 2001).  
 In each at least five independent trials per concentration (30 µM, 60 µM, 100 µM, 200 
µM, and 300 µM) per peptide, NC-1007 and its tryptophan containing variants were added to the 
bathing solution of the apical portion of the chamber. Immediately upon peptide addition, a 
response in ISC was clearly noticeable at the higher concentrations, uniformly peaking within the 
first two to three minutes after exposure, and in some cases eliciting currents greater than 25-30 
µA. In these cases after reaching the peak current a gradual decline in ISC was seen, most likely 
due to a partial polarization of the cells, conditions that would reduce the driving force for 
chloride efflux. After a minimum of 10 minutes of recording the peptide induced ISC, forskolin (2 
µM) was added both apically and basolaterally to the chamber to test for post-treatment viability 
and membrane integrity. The course of additions in a typical Ussing run is shown in Fig 4.3.  
 
       
 
Figure 4.3 Course of a typical Ussing chamber experiment 
1) post-mount equilibration 2) addition of 100 µM 1-EBIO 3) establishment of baseline current 
4) addition of peptide 5) addition of 2 µM Forskolin 
 
 MDCK monolayers exhibited a concentration-dependent increase in ISC in response to the 
addition of all of the peptides. Maximal current values as averaged over 90 second clamped 
increments between pulses were collected for each concentration in each trial (one trial 
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consisting of one peptide tested at five concentrations), and cumulatively used to determine the 
best fit in the modified Hill equation after subtraction of post-EBIO baseline values.  
 Generally, as shown in the plots of peptide concentration relative to Δ ISC (Fig. 4.4), 
complete saturation was not reached using the concentrations tested. In all cases except in that of 
NC1007 S21W, constraining the IMAX value to the mean ISC value at 300 µM + one standard 
deviation produced the best fit of a Hill equation to the data. The ISC value of constrained fits as 
well as values for K½, and the Hill coefficient (n) were determined by the best fit of the modified 
Hill equation given in Chapter 3, as obtained using SigmaPlot (Systat Software, San Jose, CA) 
and presented with their respective standard error of the mean (SEM) in Table 4.2.  
 
 
 
 
  
Figure 4.4: Concentration-dependence of peptide on peak ΔIsc across MDCK epithelial cells 
Symbols represent the mean, and error bars represent ± SEM for a minimum of four observation 
per data point. Solid lines represent the best fit of a modified Hill equation to the data. Note that 
though data points are presented, there is no demonstrated fit of the mathematical model given to 
the data derived from NC-1007 S21W.  
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Table 4.2 Kinetic Parameters of W-Substituted NC1007 Peptides 
* IMAX values were constrained to less than or equal to the mean value at the highest 
concentration tested for each peptide (300 µM in all cases) + 1 standard deviation. It is assumed 
for the sake of the experiments conduced that IMAX approximates ΔISC values observed at the 
highest tested concentration.   
**Kinetic parameter data not available for NC-1007 S21W 
Peptide IMAX (µA)* K½  (µM) Hill coefficient (n)  
NC-1007 WT 25.4 ± 9.4 
 
178 ± 79 
 
2.07 ± 0.77 
 
NC-1007 S18W 28.2 ± 21.6 
 
195 ± 187 
 
1.84 ± 1.15 
 
NC-1007 S19W 36.7 ± 17.9 
 
176 ± 111 
 
1.86 ± 0.87 
 
NC-1007 G20W 32.3 ± 8.2 
 
149 ± 50 
 
1.98 ± 0.62 
 
NC-1007 S21W n/d** 
 
n/d** 
 
n/d** 
 
 
Despite multiple attempts, NC-1007 S21W data could not reasonably be fit by the Hill 
equation presented. Attempted fits using SigmaPlot software yielded results with kinetic 
parameters vastly different than any related sequences. All modified peptides appeared to be best 
fit with a higher IMAX value than their unmodified counterpart. Interestingly, while unconstrained 
K½ and Hill values given in Table 4.2 remain roughly in the same range for all peptides 
excepting NC-1007 S21W (ranging from around 150 to 200 µM and 1.84 to 2.1, respectively), 
there appears to be uniquely consistent patterns in some cases. Substituting a Trp for serine at 
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position 18 in the sequence, while slightly increasing K½ and decreasing the Hill coefficient, 
produced an overlay to the line of fit rendered for the data of the native sequence peptide, 
suggesting that this slight decrease in Hill and increase in K½ have a net effect of a very similar 
concentration-dependence curve as shown in Fig. 4.4 below. Similarly, a tryptophan substitution 
in either the 19th or the 20th position in the peptide sequence (for serine and glycine, 
respectively), produced a similar net effect in either case, though clearly distinct from those of 
the unmodified sequence or NC-1007 S18W.  
 Though the Hill coefficient is generally assumed to be an indicator of cooperativity in 
channel formation, the data presented with Hill coefficients in all cases exceeding a value of one 
are alone insufficient to characterize channel formation, but do reflect that the channel 
structuring process is more complicated than a simple bimolecular interaction.  
 
 RP-HPLC Studies 
Peptide samples were analyzed by HPLC. Monomers elute as sharp peaks while 
aggregates elute as broad poorly defined humps. Fig. 4.5 shows the chromatographic profiles of 
all peptides tested, including that of a previously studied peptide, NC-1120, known to be in a 
predominately monomeric form (Broughman, 2002). Previous studies showed that CK4-M2GlyR 
(NC-1007) adopted multiple assemblies in water. The three major species observed were 
monomer, dimer and some higher form, perhaps tetramer. We hypothesized that the substitution 
of a Trp near the C-terminus may reduce the aggregation propensity of the carboxy-teminal lysl-
adducted peptides. Results indicate, however, that this substitution had little effect on the 
maintenance of a monomeric solute, and subsequent reanalysis of various obtained fractions 
along the HPLC profile simply produces an identical chromatograph to the sample from which 
such fractions were initially obtained. These results suggest that aggregate dominates all tested 
variants of NC-1007 in solution, as no amount of collection and reanalysis of peptide sample was 
capable of reducing the profile to a well-defined peak such as that demonstrated in the 
comparison sequence, NC-1120 (Broughman et al., 2002).  
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A: NC-1120 
B: NC-1007 
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C: NC-1007 S18W 
D: NC-1007 S19W 
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Figure 4.5 (A-F): HPLC chromatographs of Trp-substituted peptides  
E: NC-1007 G20W 
F: NC-1007 S21W 
 36 
All experimental peptides demonstrate aggregation relative to a known monomeric sequence (A: 
NC-1120), and the unmodified sequence, known to form solution aggregates (B: NC-1007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
 The aim of these studies was to explore whether tryptophan residue substitutions in the 
C-terminal region of NC-1007 (CK4-M2GlyR; PARVGLGITTVLTMTTQSSGSRAKKKK) 
would ameliorate solution aggregation while optimizing positioning of the transmembrane 
portion of the sequence such as to induce desirable changes in kinetic parameters of ion flux 
(e.g., increase in IMAX, reduced K½). Such an approach was employed successfully on peptides 
containing the N-terminally adducted lysines. Peptides such as NC-1130 (NK4-M2GlyR T19R, 
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S22W; KKKKPARVGLGITTVLTMRTQW) showed little solution aggregation and showed an 
increased IMAX and a reduced K½ relative to the native sequence. Unfortunately this sequence was 
no longer anion selective. NC-1007 is anion selective and by incorporating these substitutions in 
the region known to promote aggregation we hypothesized that aggregation could be reduced 
without reducing selectivity. 
The Trp-substituted variants of the peptides analyzed in this study, produced mixed 
effects with regard to their electrophysiological properties. One unexpected outcome 
demonstrated by electrophysiological studies, is the approximate overlap of data fit to a modified 
Hill plot between peptide pairs. The S18W substitution gave results similar to the unmodified 
sequence.  The S19W and G20W sequences produced slightly higher currents but their 
concentration for half-maximal currents were unchanged over the unmodified NC-1007.  The 
S21W variant gave atypical results in that at lower concentrations it behaved more like NC-1007 
but at the highest concentration it produced currents even higher than any of the other sequences. 
These complementary profiles suggest an interesting correlation between concentration-
dependent effects on ion flux and placement of tryptophan in the peptide sequence. As discussed 
previously, a typical membrane-spanning helical domain is composed of about 18-20 amino acid 
residues. However, the membrane can “thin” such that as few as 14 residues may span the 
membrane in helical structure (Hille, 2001). Though Arg has been noted to play a role in 
defining the barrier of the transmembrane segment, hydrophobic Trp has also been shown to be 
important in defining pore registry within the membrane. It is possible that the similar kinetic 
profile of S18W to that of the wild type may be explained by the propensity of the peptide to 
span the membrane from Arg to Arg (18 intermediate residues), rather than sufficiently driving 
the membrane to “thin” to its minimal capacity in order to contain merely the 14 residues 
between the registry-defining N-terminal Arg and the Trp in the 18th position in the sequence. 
Setting aside any assumptions about how the bulky aromatic Trp residue might affect the channel 
structure and kinetics, this identification in registry could explain the similar overlay of NC1007 
S18W to that of NC1007. 
 It is also conceivable that an elongating shift in tryptophan position from the 18th to the 
19th or 20th sequential position might allow for a more energetically favorable conformer in 
which the tryptophan was sufficiently distant from the N-terminal arginine to define the span as 
hypothesized. Such a schema may explain the similarity in profile between NC1007 S19W and 
NC1007 G20W (a single amino acid shift). Notably, however, NC1007 S21W behaved like none 
of its Trp-substituted counterparts, defying the mathematical model used to describe all other 
experimental peptides studied, suggesting a more complicated interaction than that described by 
the model. The proclivity of both Arg and Trp to lie at the membrane interface could perhaps 
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shed light on one facet of this notable difference. Notably, NC1007 S21W is the only peptide 
studied in which the C-terminal Arg and substituted Trp are adjacent to one another. It may be 
problematic in that neither of the two residues clearly and consistently defines the registry in this 
sequence, leading to inconsistency not only in the membrane placement of each peptide forming 
the channel, but also the position of a single peptide (or channel) over time. 
 Trp-substituted variants had no measurable effect on solution aggregation. Solution 
aggregation prevents HPLC purification of the desired product since any purified and dried 
material upon redissolving in water regenerates the aggregated state and produces a replicate 
profile identical to the initial profile. The similarity in profile upon repeat runs suggests not only 
that the peptide is likely to continue aggregating after fractionation, but also that there appears to 
be no concentration-dependent change in the relative amount of aggregate peptide in solution.  
 To further characterize the aggregate form of the peptides, the UV absorbance properties 
of the Trp-containing sequences were analyzed. The free Trp control, which is completely 
solvent accessible, gives a sharp absorbance peak centered around 278-280 nm. In contrast all of 
the peptides show much broader peaks with the added absorbance extending into the lower 
wavelengths, suggest of a blue shift for some of the tryptophan residues. One could conceivable 
image two peaks merging to give the resultant peak. Since there are no other chromophores in 
the peptides, this result indicates that the Trps are present both in solvent exposed and buried 
environments. All of the profiles look similar suggesting that the location of the added 
tryptophan relative to the hydrophobic and hydrophilic faces of the helices has no bearing on 
their solvent accessibility in the aggregate state. 
To examine potential positional effects of the tryptophan substitutions in the amphiphilic 
helix, the sequences were examined visually with regard to their location in the hydrophic face, 
or the hydrophilic face that would exist when the helices self-assemble to form the channel pore.  
Under these conditions. helix wheel representations of NC-1007 and Trp-substituted variants 
were modeled using Emboss Pepwheel software from Alan Bleasby (European Bioinformatics 
Institute, Hinxton, Cambridge, United Kingdom; Rice et al., 2000), omitting the C-terminal tetra-
lysyl tail. Residues were plotted with an 18-step, 5-turn output with the hydrophilic residues 
(VMCILYFW) indicated as blue squares,  the hydrophobic residues (EDKRHQPNATSG) by 
black octagons, and the highly-hydrophobic substituted tryptophan (W; in relevant sequences) by 
a red diamond for clarity. All determinations of hydrophobicity/hydrophilicy were determined 
based upon the Wimley-White hydrophobicity index (Wimley & White, 1996).  The wheels are 
arbitrarily bisected into the hydrophobic quadrant (B) (5/11 residues) and the hydrophilic 
quadrant (L) (11/12 residues). 
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Figure 4.6 (opposite): Helix Wheel models of w-substituted NC1007 variants.  
Helical wheel models are shown with hydrophilic residues highlighted in blue squares and 
hydrophobic residues noted in black circles. Red diamonds represent the location of the 
substituted tryptophan residue in the α–helix. Sequences are read beginning with the bottom 
residue at 12 o’clock (P in all presented cases), and following the connecting lines 
counterclockwise through the helix. The bisectional divide represents approximations of the 
hydrophilic (L) and hydrophobic (B) faces of the helix.  
All hydrophilicity/hydrophobicity data collected from the Wimley-White hydrophobicity index 
(Wimley & White, 1996).  
 
 
 
Figure 4.7  UV/Vis spectrophotometric profiles  
Profile of free tryptophan (w; red), and its placement in the hydrophobic (NC1007 S18W; blue) 
or hydrophilic (NC1007 G20W; black) face of the transmembrane α-helix.  
 
 
 UV/Vis spectrometric profiles, when compared to free tryptophan in 50% TFE solution, 
demonstrate a merged peak including a violet shift, presumably caused by protection of 
tryptophan residues within the hydrophobic center of peptide aggregates. The effect was virtually 
identical regardless of the highly hydrophobic tryptophan residue’s position in either the 
hydrophobic or hydrophilic face of the native peptide’s α-helix. This suggests that at least some 
(and possibly all) aggregating peptide will orient such that the pore-defining tryptophan faces 
into the core of the aggregate, but roughly to the same extent regardless of position in the helix. 
The latter may be possible if the notable hydrophobic force of tryptophan is sufficient, even 
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when located among hydrophilic residues, to drive peptide orientation during aggregation such 
that it consistently faces inward. Extended studies into aggregate structure such as molecular 
modeling experiments will provide further evidence as to the mechanism behind aggregate 
peptide orientation.  
In summary, although C-terminal tryptophan substitutions to NC1007 appeared to 
produce mild effects on kinetic parameters, the substitutions did little to reduce the propensity of 
the peptide to aggregate in solution and instead remain monomeric. This endpoint is vital from a 
drug-development perspective, and further study into the reduction of aggregation propensity in 
CK4-M2GlyR peptides or the increase of NK4-M2GlyR selectivity still shows potential in 
leading to the development of a peptide capable of effectively and reliably serving as a 
replacement for defective ion channels in patients expressing, in particular Cl- specific 
channelopathies, such as those which result in cystic fibrosis.   
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